Exact Sciences launches Cancerguard MCED test

Jaime LaMontagne named chief marketing officer of Astrin Biosciences

Jaime LaMontagne was appointed chief marketing officer of Astrin Biosciences.

August 08, 2025

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

Mailing a stool-based test directly to people’s homes was the most effective of four strategies for increasing colorectal cancer screening rates, according to a study by UCLA researchers aimed at identifying the best approach to promote CRC screening in adults ages 45 to 49.

August 08, 2025

Vol.51 No.31

Clinical Roundup

Blood tests show potential for CRC detection, but follow-up falls short

About half patients completed a follow-up colonoscopy within six months of taking a blood-based colorectal cancer screening test, according to a study by investigators at UCLA Health Jonsson Comprehensive Cancer Center.

August 01, 2025

Vol.51 No.30

Drugs & Targets

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.

April 04, 2025

Vol.51 No.13

Clinical Trials & Tribulations

New colorectal cancer screening strategies must advance the standard of care

Colorectal cancer is the second leading cause of cancer-related death in the United States. Accurate and early detection of CRC and precancerous lesions is critical for reducing incidence and preventing deaths from this disease.

Blood test predicts prognosis for advanced prostate cancer, study finds

A new study, published in Nature Communications and led by the University of Minnesota Medical School and Duke University, found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the blood of certain patients with advanced, metastatic prostate cancer.

December 13, 2024

Vol.50 No.46

Exact Sciences launches Cancerguard MCED test

YOU MAY BE INTERESTED IN

Jaime LaMontagne named chief marketing officer of Astrin Biosciences

Mailing at-home test kits is more effective at getting younger adults to participate in CRC screening, UCLA study finds

Blood tests show potential for CRC detection, but follow-up falls short

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

New colorectal cancer screening strategies must advance the standard of care

Blood test predicts prognosis for advanced prostate cancer, study finds

Renew today!

Subscriber content

Never miss an issue!

Login